GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » Gross Margin %

Cosmo Pharmaceuticals NV (XSWX:COPN) Gross Margin % : 56.78% (As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Cosmo Pharmaceuticals NV's Gross Profit for the six months ended in Jun. 2023 was CHF24.2 Mil. Cosmo Pharmaceuticals NV's Revenue for the six months ended in Jun. 2023 was CHF42.6 Mil. Therefore, Cosmo Pharmaceuticals NV's Gross Margin % for the quarter that ended in Jun. 2023 was 56.78%.


The historical rank and industry rank for Cosmo Pharmaceuticals NV's Gross Margin % or its related term are showing as below:

XSWX:COPN' s Gross Margin % Range Over the Past 10 Years
Min: 76.73   Med: 83.13   Max: 89.11
Current: 80.53


During the past 13 years, the highest Gross Margin % of Cosmo Pharmaceuticals NV was 89.11%. The lowest was 76.73%. And the median was 83.13%.

XSWX:COPN's Gross Margin % is ranked better than
92.5% of 987 companies
in the Drug Manufacturers industry
Industry Median: 46.24 vs XSWX:COPN: 80.53

Cosmo Pharmaceuticals NV had a gross margin of 56.78% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Cosmo Pharmaceuticals NV was -0.50% per year.


Cosmo Pharmaceuticals NV Gross Margin % Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Gross Margin % Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.11 85.20 82.87 76.73 81.62

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.46 96.33 58.51 97.46 56.78

Competitive Comparison of Cosmo Pharmaceuticals NV's Gross Margin %

For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo Pharmaceuticals NV's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Cosmo Pharmaceuticals NV's Gross Margin % falls into.



Cosmo Pharmaceuticals NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Cosmo Pharmaceuticals NV's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=82.2 / 100.748
=(Revenue - Cost of Goods Sold) / Revenue
=(100.748 - 18.516) / 100.748
=81.62 %

Cosmo Pharmaceuticals NV's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=24.2 / 42.592
=(Revenue - Cost of Goods Sold) / Revenue
=(42.592 - 18.409) / 42.592
=56.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Cosmo Pharmaceuticals NV  (XSWX:COPN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Cosmo Pharmaceuticals NV had a gross margin of 56.78% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Cosmo Pharmaceuticals NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines